文献速递肾小球疾病

多组学揭示终末回肠来源IgA+β7+细胞在IgA肾病中的致病作用

Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy.
PubMed 文献 · Kidney Int · 2026-01-20

本研究通过多组学分析99例IgA肾病患者和121例健康对照,发现终末回肠来源的IgA+β7+浆母细胞/浆细胞产生半乳糖缺陷型IgA1(Gd-IgA1)并与疾病严重程度相关;抗α4β7单抗可在小鼠模型中减少β7+细胞和Gd-IgA1并防止系膜IgA沉积。

要点

  • 终末回肠而非升结肠的IgA+ B细胞增多,表达Gd-IgA1且O-糖基化酶失调。
  • 循环IgA+β7+浆母细胞/浆细胞增多与IgA肾病严重程度相关。
  • 抗α4β7单抗在人源化IgA肾病小鼠中减少β7+细胞和Gd-IgA1,防止系膜IgA沉积。

核心结论

  • 终末回肠失调的B细胞反应在IgA肾病中起重要作用。
  • α4β7-MAdCAM-1轴可能是IgA肾病的潜在治疗靶点。

研究设计与样本

  • 研究纳入三个独立队列共99例IgA肾病患者和121例健康对照,分析肠道和循环免疫细胞。
  • 采用配对回盲部和血液样本检测IgA表型,结合bulk RNA测序、细胞去卷积和活检空间分析。
  • 功能研究使用抗整合素α4β7单抗进行体外实验和人源化IgA肾病小鼠模型。

主要发现

  • IgA肾病患者回盲部IgA水平显著升高,富集多聚体和Gd-IgA1 O-糖型。
  • 终末回肠而非升结肠的IgA+ B细胞增加,多数表达Gd-IgA1且O-糖基化相关酶失调。
  • IgA肾病患者循环IgA+ B细胞基因表达特征更接近终末回肠来源而非升结肠或扁桃体来源。
  • 整合素β7被鉴定为终末回肠来源细胞的生物标志物,IgA+β7+浆母细胞/浆细胞增加且与疾病严重程度相关。
  • 小鼠模型中抗α4β7单抗减少β7+细胞和Gd-IgA1水平,诱导派尔集合淋巴结萎缩,减少循环β7+浆母细胞/浆细胞,防止系膜IgA沉积。

临床怎么用

  • 终末回肠来源的IgA+β7+细胞及整合素β7可作为IgA肾病疾病活动度的潜在生物标志物。
  • α4β7-MAdCAM-1轴为IgA肾病提供了新的治疗干预方向,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) plays a key role in IgA nephropathy (IgAN), but the location of the plasma cells responsible for its production remain unknown. METHODS: To locate Gd-IgA1-producing cells, we profiled intestinal and circulating immune cells from three independent cohorts totaling 99 IgAN cases and 121 healthy controls. The IgA phenotypes-including total IgA, Gd-IgA1, IgA-IgG complexes, secretory IgA, and polymeric IgA levels were measured in paired ileocecal and blood samples. Bulk RNA sequencing, cell deconvolution, and spatial profiling of biopsies identified Gd-IgA1-producing cells in ileocecal samples and blood. Functional studies employed anti-integrin α4β7 monoclonal antibodies in vitro and in a humanized IgAN mouse model. RESULTS: We found significantly elevated levels of ileocecal IgA enriched for polymeric and Gd-IgA1 O-glycoforms in patients with IgAN. In parallel, terminal ileal rather than ascending colon IgA+ B cells were increased. Most of these cells expressed Gd-IgA1 and displayed dysregulation of enzymes involved in O-glycosylation. Furthermore, circulating IgA+ B cells in IgAN exhibited gene expression signatures more closely resembling that of terminal ileum-derived IgA+ B cells, rather than those from ascending colon or tonsil. Integrin β7 was identified as a biomarker for cells of terminal ileal origin, and there was an increase in IgA+β7+ plasmablasts/plasma cells, correlating with disease severity. In a mouse model of IgAN, anti-α4β7 monoclonal antibody reduced β7+ cells and Gd-IgA1 levels in vitro and induced attrition of Peyer's patches, decreased circulating β7+ plasmablasts/plasma cells, and prevented mesangial IgA deposition. CONCLUSIONS: Our study highlights the importance of dysregulated B cell responses in the terminal ileum in IgAN and suggests the α4β7-MAdCAM-1 axis as a potential therapeutic target.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Liu X, Wang L, Lin M, et al. Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy. Kidney Int. 2026. PMID: 41571098. doi:10.1016/j.kint.2025.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。